1. Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report, 2011.
2. Пульмонология: Национальное руководство. Под ред. А.Г.Чучалина. М.: ГЭОТАР-Медиа, 2009.
3. Бабанов С.А. Клинико-иммунологические особенности, факторы риска и прогнозирование течения хронической обструктивной болезни легких в крупном промышленном центре Среднего Поволжья. Автореф. дис. … д-ра мед. наук. Самара, 2008.
4. Amsden GW, Baird IM, Simon S, Treadway G. Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 2003; 123: 772–7.
5. Anthonisen NR, Manfreda J, Warren CPW et al. Antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204.
6. Косарев В.В., Бабанов С.А. Справочник врача-пульмонолога. Ростов-на-Дону: Феникс, 2011.
7. Monso E, Ruiz J, Rosell A, Manterola J et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152 (4 Pt 1): 1316–20.
8. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347 (7): 465–1.
9. Sethi S. Bacteria in exacerbations of chronic obstructive pulmonary disease. The Proceedings of the American Thoracic Society 2004; 1: 109–4.
10. Murphy T, Parameswaran G. Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis 2009; 49 (1): 124–31.
11. Kherad O, Rutschmann O. Viral Infections as a Cause of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation. Praxis 2010; 99 (4): 235–40.
12. Mogulkoc N, Karakurt S, Isalska B et al. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med 1999; 160: 349–53.
13. Soler N, Torres A, Ewig S et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157: 1498–505.
14. Murphy T, Brauer A, Eschberger K et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177 (8): 853–60.
15. Donaldson G, Seemungal T, Bhowmik A et al. The relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–52.
16. De Serres G, Lampron N, La Forge J et al. Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. J Clin Virol 2009; 46 (2): 129–33.
17. Puhan MA, Vollenweider D, Latshang T et al. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir Res 2007; 8: 30.
18. Козлов Р.С., Сивая О.В., Кречикова О.И., Иванчик Н.В. Динамика резистентности Streptococcus pneumoniae к антибиотикам в России за период 1999–2009 гг. (Результаты многоцентрового проспективного исследования ПеГАС.) Клин. микробиология и антимикроб. химиотерапия. 2010; 12 (4).
19. Сидоренко С.В. Проблемы этиотропной терапии внебольничных инфекций дыхательных путей. Cons. Med. 2002; 1: 4–10.
20. Практическое руководство по антиинфекционной химиотерапии. Под ред. Л.С.Страчунского, Ю.Б.Белоусова, С.Н.Козлова. М.: Каламос, 2007.
21. Чучалин А.Г., Синопальников А.И., Яковлев С.В. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Клин. микробиология и антимикроб. химиотерапия. 2003; 3: 198–224.
22. Jones ME, Blosser-Middleton RS, Critchley IA et al. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000–2001. Clin Microbiol Infect 2003; 9: 590–9.
23. Uriate SM, Molestina RE, Miller RD et al. Effect of macrolide antibiotics on human endothelial cells activated by Chlamidia pneumonia infection and tumor necrosis factor-alfa. J Infect Dis 2002; 185: 1631–6.
24. Hodge S, Hodge G, Brozyna S et al. Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur Respir J 2006; 28 (3): 486–95.
25. Sugiyama K, Shirai R, Mukae H et al. Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells. Clin Exp Immunol 2007; 147: 540–6.
26. Amsden GW. Anti-inflammatory effects of macrolides an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55 (1): 10–21.
27. Parnham MJ, Culić O, Eraković V et al. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonarydisease by short-term azithromycin treatment. Eur J Pharmacol 2005; 517 (1–2): 132–43.
28. Усенко С., Бетанели Т. Эффективная антибактериальная терапия тяжелого обострения хронической обструктивной болезни легких. Врач. 2005; 10: 9–10.
29. Amsden GW, Baird, Ian M et al. Efficacy and Safety of Azithromycin vs Levofloxacin in the Outpatient Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis. Chest 2003; 123: 772–7.
30. DeAbate CA, Mathew CP, Warmer JH et al. The safety and efficacyof short cours (5-day) moxifloxacin versus asithromycin in the treatment of patients with acute exacerbacion of chronic bronchitis. Respir Med 2000; 94: 1029–103.
31. American Thoracic Society (ATS) 2011 International Conference: Abstract 22714. Presented: May 17, 2011. http://www.medscape.com/viewarticle/743283
32. Alos JI, Aracil B, Torres C et al. High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998, Spanish group for the study of Infection in the Primary Health Care Setting. J Antimicrob Chemother 2000; 45: 605–9.
33. Bakar O, Demircay Z, Yuksel M et al. The effect of azithromycin on reactive oxygen species in rosacea. Clin Exp Dermatol 2007; 32 (2): 197–200.
34. Baquero F, Garcia-Rodriguez JA, de Lomas JC, Aguilar L. Antimicrobial resistance of 914 beta-hemolytic streptococci isolated from pharyngeal swabs in Spain: results of 1-year (1996–1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogenes. Antimicrob Agents Chemother 1999; 43: 178–80.
35. Bergamini G, Cigana C, Sorio C et al. Effects of azithromycin on glutathione S-transferases in cystic fibrosis airway cells. Am JRespir Cell Mol Biol 2009; 41 (2): 199–206.
36. Cigana C, Nicolis E, Pasetto M et al. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. BiochemBiophys Res Commun 2006; 350 (4): 977–82.
37. Cornaglia G, Fontana R. Epidemiological survey of bacterial resistance in upper respiratory tract infections in Italy. Int J Antimicrob Agents 2000; 16: 259–62.
38. Culi O, Erakovi V, Cepelak I et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthyhuman subjects. Eur J Pharmacol 2002; 450 (3): 277–89.
39. de Azavedo JC, Yeung RH, Bast DJ et al. Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada. Antimicrob Agents Chemother 1999; 43: 2144–7.
40. Hand WL, Hand DL, Vasquez Y. Increased polymorphonuclear leukocyte respiratory burst function in type 2 diabetes. Diabet Res Clin Pract 2006. [Epub ahead of print.]
41. Kaplan EL, Johnson DR, Del Rosario MC, Horn DL. Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997. Pediatr Infect Dis 1999; 18: 1069–72.
42. Kim D-Y, Takeuchi K, Ishinaga H et al. Roxithromycin supresses mucin gene expression in epithelial cells. Pharmacology 2004; 72: 6–11.
43. Lieberman D, Lieberman D, Shmarkov O et al. Serological evidence of Legionella species infection in acute exacerbation of COPD. Eur Respir J 2002; 19: 392–7.
44. Melo-Cristino J, Fernandes ML. Streptococcus pyogenes isolated in Portugal: macrolide resistance phenotypes and correlation with T types. Portuguese Surveillance Group for Study of Respiratory Pathogenes. Microb Drug Resist 1999; 5: 219–25.
45. Miravitlles M, Espinosa C, Fernandez-Laso E et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116: 40–6.
46. Murphy DM, Forrest IA, Corris PA et al. Azithromycin attenuates effects of lipopolysaccharide on lung allograft bronchial epithelial cells. J Heart Lung Transplant 2008; 27: 1210–6.
47. Peters DH, Friedel HA, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drug 1992; 44: 750–99.
48. PROTEKT Study Database. 2001. http:http://w.w.w.protekt.org
49. Schito GC, Debbia EA, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project. J Antimicrob Chemother 2000; 46 (Suppl. T1): 3–9.
50. Schito GC. Is antimicrobial resistance also subject to globalization? Clin Microbial Infect 2002; 8 (Suppl. 3): 1–8.
51. Shimuzu T, Shimuzu S, Hattori R et al. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epthelilal cells. Am J Respir Crit Care Med 2003; 168: 581–7.
52. Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 2004; 117 (Suppl. 9A): 5S–11S.
53. Tsai WC, Rodriguez ML, Young KS et al. Azithromycin blocksneutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med 2004; 170: 1331–9.
54. Goh SK, Johan A, Cheong TH, Wang YT. A prospective study of infections with atypical pneumonia organisms in acute exacerbations of chronic bronchitis. Ann Acad Med Singapore 1999; 28: 476–80.

В.В.Косарев, С.А.Бабанов 

Кафедра профессиональных болезней и клинической фармакологии ГБОУ ВПО Самарский государственный медицинский университет Минздрава РФ